EADV Cleara about Psoriasis
Patients with moderate-to-severe psoriasis do not believe clearance of their skin is a realistic treatment goal: results from the largest global psoriasis patient survey
Warren R.B.(1), Armstrong A.(2), Boehncke W-H.(3), Fernández-Peñas P.(4), Bewley A.(5), Romiti R.(6), Rajagopalan M.(7), Jarvis S.(8), Hillmann O.(9), Boyd E.(10), Sodha M.(11), Vaid B.(12), Huneault L.(13), Fox T.(14)
(1)The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, (2)Department of Dermatology, Keck School of Medicine at USC, University of Southern California, Los Angeles, United States, (3)Geneva University Hospital, Division of Dermatology and Venerology, Department of Internal Medicine Specialities, Geneva, Switzerland, (4)The University of Sydney, Westmead Hospital, Department of Dermatology, Westmead, Australia, (5)Whipps Cross University Hospital and The Royal London Hospital, Department of Dermatology, London, United Kingdom, (6)Department of Dermatology, University of São Paulo, Brazil, (7)Apollo Hospitals, Department of Dermatology, Chennai, India, (8)Richford Gate Medical Practice, London, United Kingdom, (9)EUROPSO, Düsseldorf, Germany, (10)National Psoriasis Foundation, VP Strategic Alliances and Clinical Affairs, Portland, United States of America, (11)GfK, Basel, Switzerland, (12)Novartis Pharma AG, Communications, Basel, Switzerland, (13)Novartis Pharma AG, Public Relations, Basel, Switzerland, (14)Novartis Pharma AG, Basel, Switzerland
